Key regions: United Kingdom, Germany, France, South Korea, Italy
The COVID-19 Vaccines market in Australia & Oceania is rapidly developing as the region is working towards vaccinating its population against the virus.
Customer preferences: As in other parts of the world, there is a high demand for COVID-19 vaccines in Australia & Oceania. People are eager to get vaccinated as soon as possible to protect themselves and their loved ones from the virus. The preference for vaccines varies across countries in the region, with some countries preferring certain types of vaccines over others.
Trends in the market: Australia was one of the first countries in the region to start vaccinating its population. The country has secured a large number of doses of the Pfizer/BioNTech vaccine as well as the AstraZeneca vaccine. The government has also announced plans to manufacture the AstraZeneca vaccine locally, which will boost the vaccine supply in the country. In New Zealand, the vaccination campaign started in February 2021, with border workers being the first to receive the vaccine. The country has secured enough doses of the Pfizer/BioNTech vaccine to vaccinate its entire population. In other parts of the region, such as Papua New Guinea and Fiji, the vaccination campaign has been slow due to a lack of vaccine supply. However, efforts are being made to increase the vaccine supply in these countries.
Local special circumstances: Australia & Oceania is a diverse region with different healthcare systems and infrastructure. This has led to variations in the speed and effectiveness of the vaccination campaigns across countries. Some countries have faced challenges in distributing the vaccines to remote and rural areas, while others have struggled with vaccine hesitancy among certain groups of the population.
Underlying macroeconomic factors: The COVID-19 pandemic has had a significant impact on the economies of countries in the region. The vaccination campaigns are seen as a key factor in the economic recovery of these countries. Governments are investing in vaccine procurement and distribution as part of their efforts to stimulate economic growth. The success of the vaccination campaigns will also have an impact on the region's tourism industry, which has been hit hard by the pandemic.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
